Zinc Sulfate for Human Papillomavirus (HPV)

Spectrum Health Hospitals

Status

Terminated

Conditions

Human Papilloma Virus

Treatments

Dietary Supplement: Zinc Sulfate

Other: Placebo (Gelatin Tablet)

Study type

Interventional

Funder types

Other

Identifiers

NCT03404310

HPV-Zinc

Details and patient eligibility

About

The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.

Full description

Upon enrollment eligible participants will be randomized and given a three-month supply of zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at enrollment and upon study completion. Patients will also be asked to complete short questionnaires and to make study staff aware of any side effects they should experience.

Enrollment

21 patients

Sex

Female

Ages

21 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR
Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR
Positive hrHPV on routine screening (positive HPV will be assumed to be high grade)

Exclusion criteria

Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization)
Pregnant patients
Breastfeeding patients
Immunocompromised patients